|Mr. Kenneth T. Mills||CEO, Pres & Director||1.04M||13.89M||1975|
|Mr. Vittal K. Vasista||Chief Financial Officer||634.07k||8.77M||1968|
|Mr. Curran M. Simpson||Sr. VP of Product Devel. & Chief Technology Officer||590.82k||4.13M||1962|
|Dr. Olivier Danos||Chief Scientific Officer||631.03k||928.3k||1958|
|Dr. Stephen Yoo||Consultant||573.71k||6.25M||1978|
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
REGENXBIO Inc.’s ISS Governance QualityScore as of April 1, 2019 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 9.